CSF1R inhibition, using agents like pexidartinib, reduces M2‐like TAMs and reprograms the immune landscape to enhance anti‐tumor responses.[91, 92] Similarly, targeting the CCL2/CCR2 axis to block TAM recruitment shows promise in reducing tumor growth. The gene discussed is CCL2; the disease is neoplasm.